clinical trial · NCT07024641
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
GigaGen, Inc.·phase1·recruiting·n = 48
Hepatitis B Virus InfectionGIGA-2339Placebo
brief summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
started
Nov 13, 2024
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Mar 18, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol